Literature DB >> 17161521

The economic costs of overactive bladder in Germany.

Theodor Klotz1, Bernd Brüggenjürgen, Martin Burkart, Ansgar Resch.   

Abstract

OBJECTIVE: To estimate the annual direct costs of overactive bladder (OAB) in Germany from a societal perspective.
METHODS: Direct costs were calculated based on prevalence figures and medical resource utilisation due to hospitalisation, office-based physician visits, visits to other health care professionals, medication, medical aids and devices, and nursing care.
RESULTS: A total of 6.48 million adults>or=40 yr of age in Germany are affected by OAB, and 2.18 million of these individuals experience incontinence. The annual incidence of comorbidities attributable to OAB is 310,000 for skin infections, 40,000 for falls, 12,000 for fractures, and 26,000 for depression (based on 2004 census data). Direct OAB-related costs per year are euro3.98 billion, with euro1.76 billion covered by statutory health insurance, euro1.80 billion by nursing care insurance, and euro0.41 billion by the patients. Nursing care accounts for euro1.80 billion of total costs (45%), devices account for euro0.68 billion (17%), physician visits account for euro0.65 billion (16%), complications account for euro0.75 billion (19%), and medication accounts for euro0.08 billion (2%).
CONCLUSION: OAB imposes a substantial economic burden on German health and nursing care, insurance, and on patients with OAB. Direct annual costs are comparable to those of other chronic diseases such as dementia or diabetes mellitus.

Entities:  

Mesh:

Year:  2006        PMID: 17161521     DOI: 10.1016/j.eururo.2006.11.040

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

1.  [Economic importance of postoperative urinary incontinence].

Authors:  V Lent; M Schultheis
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

2.  Transcutaneous electrical nerve stimulation: an effective treatment for refractory non-neurogenic overactive bladder syndrome?

Authors:  Marc Tellenbach; Marc Schneider; Livio Mordasini; George N Thalmann; Thomas M Kessler
Journal:  World J Urol       Date:  2012-05-24       Impact factor: 4.226

3.  [Prediction of overactive bladder treatment outcome by using long-term urodynamics].

Authors:  S Wille; D Tenholte; O A Cornely; N Muthen; U-H Engelmann; J Mehner; O Eminaga; J Herden; P Schumacher; J Paas
Journal:  Urologe A       Date:  2014-12       Impact factor: 0.639

4.  [Sacral neuromodulation for refractory overactive bladder].

Authors:  Arndt van Ophoven
Journal:  Urologe A       Date:  2018-11       Impact factor: 0.639

5.  [Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis].

Authors:  C Frohme; Z Varga; P Olbert; A J Schrader; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2010-05       Impact factor: 0.639

6.  Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.

Authors:  Thomas M Kessler; Lucas M Bachmann; Christoph Minder; David Löhrer; Martin Umbehr; Holger J Schünemann; Alfons G H Kessels
Journal:  PLoS One       Date:  2011-02-23       Impact factor: 3.240

7.  Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies.

Authors:  Matthias Oelke; Richard Berges; Sandra Schläfke; Martin Burkart
Journal:  World J Urol       Date:  2014-06-18       Impact factor: 4.226

Review 8.  The association between overactive bladder and diuretic use in the elderly.

Authors:  O James Ekundayo
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

Review 9.  [Botulinum toxin in nonneurogenic bladder dysfunction].

Authors:  U Mehnert; B Schurch
Journal:  Urologe A       Date:  2009-03       Impact factor: 0.639

Review 10.  Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction.

Authors:  Mohammad Sajjad Rahnama'i; Gommert A Van Koeveringe; Philip E Van Kerrebroeck
Journal:  Nephrourol Mon       Date:  2013-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.